🇺🇸 United States Country × Condition
acute myeloid leukemia Clinical Trials in United States
Active clinical trials for acute myeloid leukemia with research sites in United States. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 30 // Recruiting: 30 Phases: Phase 1, Phase 2 // Updated: Daily
Total Trials
30
Recruiting Now
30
Country
🇺🇸 United States
Active Trials in United States (30)
NCT06551584 Phase 1
Recruiting
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Enrollment
24 pts
Country
🇺🇸 United States
Stanford University
View Trial → NCT07374029 Phase 1
Recruiting
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Enrollment
30 pts
Country
🇺🇸 United States
David Avigan
View Trial → NCT06146257 Phase 1
Recruiting
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Enrollment
48 pts
Country
🇺🇸 United States
GluBio Therapeutics Inc.
View Trial → NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT06129734 Phase 1, Phase 2
Recruiting
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Enrollment
20 pts
Country
🇺🇸 United States
Benjamin Tomlinson
View Trial → NCT02508038 Phase 1
Recruiting
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Enrollment
22 pts
Country
🇺🇸 United States
University of Wisconsin, Madison
View Trial → NCT03802695 Phase 1
Recruiting
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Enrollment
300 pts
Country
🇺🇸 United States
Orca Biosystems, Inc.
View Trial → NCT04659616 Phase 1
Recruiting
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Enrollment
32 pts
Country
🇺🇸 United States
OHSU Knight Cancer Institute
View Trial → NCT04065399 Phase 1, Phase 2
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Enrollment
447 pts
Country
🇺🇸 United States
Syndax Pharmaceuticals
View Trial → NCT06543381 Phase 1
Recruiting
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Enrollment
15 pts
Country
🇺🇸 United States
City of Hope Medical Center
View Trial → NCT06152809 Phase 1
Recruiting
CIML NK Cells With Venetoclax for AML
Enrollment
10 pts
Country
🇺🇸 United States
Dana-Farber Cancer Institute
View Trial → NCT04243785 Phase 1
Recruiting
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Enrollment
80 pts
Country
🇺🇸 United States
Edgewood Oncology Inc.
View Trial → NCT07046078 Phase 2
Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Enrollment
20 pts
Country
🇺🇸 United States
Fred Hutchinson Cancer Center
View Trial → NCT06279572
Recruiting
Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
Enrollment
80 pts
Country
🇺🇸 United States
Mayo Clinic
View Trial → NCT06317649 Phase 2
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Enrollment
147 pts
Country
🇺🇸 United States
National Cancer Institute (NCI)
View Trial → NCT06191978 Phase 1
Recruiting
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment
40 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT06399640 Phase 1
Recruiting
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment
60 pts
Country
🇺🇸 United States
Vanderbilt-Ingram Cancer Center
View Trial → NCT06297941 Phase 1
Recruiting
Study of REM-422 in Patients With AML or Higher Risk MDS
Enrollment
100 pts
Country
🇺🇸 United States
Remix Therapeutics
View Trial → NCT06950034 Phase 1
Recruiting
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Enrollment
105 pts
Country
🇺🇸 United States
Solu Therapeutics, Inc
View Trial → NCT05183035 Phase 3
Recruiting
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Enrollment
130 pts
Country
🇺🇸 United States
PedAL BCU, LLC
View Trial → NCT06945042
Recruiting
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Enrollment
120 pts
Country
🇺🇸 United States
Wake Forest University Health Scien...
View Trial → NCT07304011 Phase 2
Recruiting
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Enrollment
28 pts
Country
🇺🇸 United States
University of California, Davis
View Trial → NCT04293562 Phase 3
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Enrollment
1,186 pts
Country
🇺🇸 United States
Children's Oncology Group
View Trial → NCT06059391 Phase 2
Recruiting
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment
216 pts
Country
🇺🇸 United States
City of Hope Medical Center
View Trial → NCT06357182 Phase 1
Recruiting
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Enrollment
30 pts
Country
🇺🇸 United States
OHSU Knight Cancer Institute
View Trial → NCT03921047
Recruiting
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Enrollment
250 pts
Country
🇺🇸 United States
University of Southern California
View Trial → NCT07439211 Phase 1
Recruiting
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Enrollment
48 pts
Country
🇺🇸 United States
Jacqueline Garcia, MD
View Trial → NCT05010122 Phase 1, Phase 2
Recruiting
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Enrollment
42 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT05580601 Phase 1, Phase 2
Recruiting
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Enrollment
20 pts
Country
🇺🇸 United States
Children's Hospital Medical Center,...
View Trial → NCT07270978 Phase 1
Recruiting
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Enrollment
23 pts
Country
🇺🇸 United States
University of Virginia
View Trial → Frequently Asked Questions
How many acute myeloid leukemia clinical trials are active in United States?
There are currently 30 active clinical trials for acute myeloid leukemia with sites in United States, of which 30 are actively recruiting patients.
How can I join a acute myeloid leukemia clinical trial in United States?
To join a acute myeloid leukemia clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are acute myeloid leukemia trials in United States?
Active acute myeloid leukemia trials in United States span Phase 1, Phase 2, Phase 1, Phase 2, Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology